newsfilter
← Latest News
GlobeNewswire·

Magenta Therapeutics Reports Second Quarter Financial Results and Recent Program Highlights

– MGTA-117 Phase 1/2 clinical trial progress continues and remains consistent with earlier observations of target binding, target cell reductions, rapid drug clearance and a favorable tolerability profile; interim clinical data disclosure anticipated i